SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors digest a recent $200 million equity offering while anticipating the upcoming IZAR-1 Phase 3 trial results for its psoriatic arthritis asset. The community is actively debating the company's valuation and the potential for a near-term buyout by major pharmaceutical players following its established best-in-class performance in hidradenitis suppurativa.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck (MRK) is currently the subject of intense buyout speculation, with community discussions centering on the company's urgent need to address an impending patent cliff for its blockbuster drug, Keytruda. Investors are actively debating potential strategic acquisitionsspecifically highlighting Sellas Life Sciences (SLS) and othersas essential moves to secure long-term patent protection and maintain market dominance in oncology.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is facing intense volatility and a massive sell-off as traders react to a critical security vulnerability that potentially allowed for the creation of counterfeit coins. While the team has deployed a patch, the community is deeply divided, with some viewing the dip as a high-stakes buying opportunity and others expressing concerns that the privacy-focused nature of the chain makes it impossible to verify if the flaw was exploited.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is drawing investor attention as it navigates regulatory uncertainty regarding potential credit card interest rate caps while simultaneously expanding its footprint in blockchain and stablecoin infrastructure through strategic acquisitions. Despite these policy headwinds, the community remains focused on the firm's core fundamental strength as a digital payment backbone with durable margins and robust transaction volume growth.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending as investors weigh potential institutional accumulation against ongoing concerns over revenue growth and persistent short interest. While recent CEO leadership changes and institutional stake increases have sparked debate, the community remains divided over whether the company can successfully pivot to agentic AI and secure the large-scale government contracts needed to drive a turnaround.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML remains a central pillar of the global semiconductor industry as investors closely watch how the ongoing AI infrastructure buildout drives demand for its critical extreme ultraviolet (EUV) lithography systems. Community sentiment is currently focused on the company's long-term competitive moat and its indispensable role in the production roadmaps of major chip foundries, leading many to monitor the stock as a key benchmark for the broader semiconductor equipment sector.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson continues to face ongoing volatility as the market balances strong pipeline updates and recent regulatory approvals against persistent talc-related litigation risks. Community discussion remains polarized, with investors weighing the company's defensive stability and robust long-term earnings potential against the potential impact of ongoing legal overhangs on share performance.

iShares Trust - iShares Biotechnology ETF

iShares Biotechnology ETF

The biotech sector, represented by IBB and XBI, is currently driven by a surge in M&A activity, AI-integrated drug discovery, and high-impact clinical trial data releases. Investors and community participants are closely monitoring binary FDA events and consolidation patterns, highlighting significant interest in companies with de-risked pipelines and potential buyout candidates.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

The Grayscale Bitcoin Mini Trust ETF is trending as investors digest a volatile period of institutional outflows and shifting regulatory sentiment surrounding Bitcoin's role as a digital asset. Community members are intensely debating whether recent price fluctuations represent a long-term bottom for institutional adoption or a sign of deeper structural instability within the crypto-linked equity space.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa Inc. is attracting investor attention as a high-quality compounder, with community members actively discussing its recent technical breakout and its strategic expansion into stablecoin settlement infrastructure. While some traders monitor the stock for short-term momentum, long-term investors emphasize its entrenched global payment network and consistent cash-flow generation as a defensive anchor for their portfolios.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Zimmer Biomet Stock the Right Pick for Your Portfolio Now?

ZBH is banking on knee growth, robotics and restructuring to drive results, but can macro pressures and competition limit the upside?

Should You Continue to Hold OMCL Stock in Your Portfolio Now?

Omnicell is advancing its autonomous pharmacy vision and expanding SaaS offerings, but tariffs and fierce competition could test its growth path.

Does NVST Stock Still Deserve a Place in Your Portfolio?

Envista executes on growth priorities with new products, acquisitions and global expansion, but macro, tariff and currency headwinds remain in focus.

Illumina Stock Gains 43.7% in 2026: What's Powering the Rally?

ILMN stock's 43.7% 2026 rally is fueled by strong sequencing demand, NovaSeq X momentum and progress toward higher growth and profitability.

Here's Why Integra LifeSciences (IART) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Integra (IART) Is Attractively Priced Despite Fast-paced Momentum

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Integra (IART) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?

PODD's Omnipod 5 momentum and global growth support its outlook, but competitive pressure and macro costs may test its margin expansion plans.

What's Fueling Omnicell Stock's 52.6% Rally Over the Past Year?

OMCL's autonomous pharmacy strategy, SaaS growth and global expansion boost shares. Can rising costs and tariffs slow the momentum?

Does TNDM Stock Still Deserve a Place in Your Portfolio?

Tandem Diabetes targets diabetes market growth with a new reimbursement model and strong liquidity. Can it overcome macro and pump execution risks?

LivaNova PLC (LIVN) Hit a 52 Week High, Can the Run Continue?

LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

Integra Lifesciences Holdings Corp

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

IARTIntegra Lifesciences Holdings Corp

Fundamentals

Latest IART News